{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tesamorelin-diabetic-neuropathy","title":"Tesamorelin for Diabetic Neuropathy: Evidence Review","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy involves progressive nerve damage tied to long-term high blood sugar. Layers include axonal degeneration, myelin sheath breakdown, reduced blood flow to nerves, and impaired nerve repair signals. If your condition includes these, degeneration outpaces the body's natural repair processes. The focus here stays on pathways that might support repair rather than suppress symptoms like pain.\n\n## Why Tesamorelin might help you\n\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\n2. **Therefore for you:** If the GH axis or visceral fat layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nTesamorelin acts as a growth hormone-releasing hormone analog. It prompts the pituitary to release more growth hormone, which in turn raises IGF-1 levels. Growth hormone and IGF-1 have been linked in animal models to supporting axonal regeneration after nerve injury. If your neuropathy involves slowed nerve regrowth, this pathway could relate to repair mechanisms rather than symptom control.\n\nIn a human study of type 2 diabetes patients, 12 weeks of tesamorelin did not worsen insulin response, fasting glucose, or HbA1c compared to placebo (human data). This matters if metabolic stability is a concern alongside neuropathy. No direct link to nerve repair in diabetic neuropathy appears in available records.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Tesamorelin** → GH axis / visceral fat\n\nThe discussion centers on one layer only: potential support for GH-mediated tissue repair signals. No stacking details apply here.\n\n## What the evidence actually shows\n\nNo completed human trials test tesamorelin specifically for diabetic neuropathy (human tier: absence of data). A planned clinical trial (NCT03150511) examines tesamorelin for recovery after traumatic peripheral nerve injury, not diabetic cases; results are not yet available (human tier: planned study).\n\nOne 12-week human trial in type 2 diabetic patients found tesamorelin did not change glycemic control or insulin sensitivity versus placebo (human data, source s5). Animal studies show growth hormone can speed peripheral nerve regeneration and reduce muscle atrophy after injury (preclinical tier).\n\nFDA labels and trials report paresthesia, hypoesthesia, and peripheral neuropathy as adverse events in some patients (human tier). FAERS data links tesamorelin to higher reporting of carpal tunnel syndrome (human tier, source s18).\n\n## What scientists say\n\nResearchers note growth hormone's role in nerve regeneration from animal work. The Johns Hopkins trial aims to test whether tesamorelin improves functional outcomes after nerve repair by boosting this pathway. Scientists highlight the need for human data specific to diabetic neuropathy, which remains absent. Metabolic studies in diabetics provide reassurance on short-term glucose stability but do not address neuropathy progression.\n\n## What people say on Reddit\n\nAnecdotal reports mention side effects such as hand numbness or carpal tunnel-like symptoms during tesamorelin use; some users link these to the compound and note resolution after stopping (anecdotal tier). Discussions reference the peripheral nerve injury trial with interest in regeneration potential, but no personal accounts describe benefits for diabetic neuropathy (anecdotal tier). Posts about nerve pain often appear in unrelated contexts.\n\n## What people say on X\n\nLimited public posts discuss tesamorelin in neuropathy contexts. Mentions focus on general GH benefits or trial awareness rather than personal diabetic neuropathy experiences (anecdotal tier, sparse).\n\n## What we do not know\n\nDirect evidence on tesamorelin altering diabetic neuropathy progression, nerve conduction, or symptoms in humans is missing. Long-term effects on nerve repair in diabetic populations remain untested. Interactions with existing diabetic neuropathy treatments lack study data. Whether GH elevation translates to meaningful repair in chronic metabolic nerve damage versus acute injury stays speculative.\n\n## Safety and limits\n\nTesamorelin carries warnings for potential glucose intolerance and diabetes risk; monitoring is advised in diabetic patients (human data). It is contraindicated in active cancer or certain pituitary issues. Injection site reactions and fluid retention appear in trials. All claims here derive from available studies and labels; no compound guarantees repair or safety for any individual condition. Evidence grading separates clear human trial results from animal work and user reports.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tesamorelin-diabetic-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"No completed human trials test tesamorelin specifically for diabetic neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s0"],"source_status":"sourced","why_material":"Establishes absence of direct evidence for the condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A 12-week human trial in type 2 diabetic patients found tesamorelin did not alter insulin response or glycemic control versus placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Provides metabolic safety data relevant to diabetic readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Animal studies indicate growth hormone can accelerate peripheral nerve regeneration after injury.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Supports mechanistic rationale but does not prove human diabetic neuropathy benefit.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Tesamorelin is associated with reports of paresthesia, hypoesthesia, and peripheral neuropathy in clinical data.","section":"What the evidence actually shows","tier":"human","source_ids":["s7"],"source_status":"sourced","why_material":"Highlights potential adverse nerve-related effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users report numbness or carpal tunnel-like symptoms during tesamorelin use, sometimes resolving after discontinuation.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s29","s35"],"source_status":"sourced","why_material":"Captures user experiences separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries.","summary":"Ongoing/planned trial for traumatic nerve injury, not diabetic neuropathy.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:24:03.648Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"8e0e6de4e112963b3a44c240e786ceec91170d3473d3893393a9a91b47157c0f"},{"id":"s5","type":"pubmed","url":"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179538","title":"Safety and metabolic effects of tesamorelin in type 2 diabetic patients","quote":"Treatment of type 2 diabetic patients with tesamorelin for 12 weeks did not alter insulin response or glycemic control.","summary":"Human metabolic study in diabetics showing neutral effect on glucose control.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:24:03.648Z","link_status":"ok","quote_status":"verified","prev":"8e0e6de4e112963b3a44c240e786ceec91170d3473d3893393a9a91b47157c0f","hash":"302b8b27b3f37df95eedd0a8a447999ec830d58bfc69cf06868f9f42ec01eb8a"},{"id":"s1","type":"other","url":"https://www.foundationforpn.org/wp-content/uploads/2025/01/Tesamorelin-Therapy-to-Enhance-Axonal-Regeneration-Minimize-Muscle-Atrophy-and-Improve-Functional-Outcomes-Following-Peripheral-Nerve-Injury-and-Repair.pdf","title":"Tesamorelin Therapy for Peripheral Nerve Injury Proposal","quote":"Many animal studies have shown that growth hormone, via its downstream factors, can speed peripheral nerve regeneration following injury","summary":"Background on preclinical GH nerve regeneration data.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:24:03.648Z","link_status":"ok","quote_status":"unverified","prev":"302b8b27b3f37df95eedd0a8a447999ec830d58bfc69cf06868f9f42ec01eb8a","hash":"b83416e7e2f9df6f9dd2d888a91b2df4982cb68216851eaa4be01fd0cc9787e8"},{"id":"s7","type":"other","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf","title":"EGRIFTA (tesamorelin) FDA Label","quote":"Hypoesthesia 4.2% vs 1.5% placebo; Neuropathy peripheral listed in adverse reactions.","summary":"Adverse event data including nerve symptoms.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:24:03.648Z","link_status":"ok","quote_status":"unverified","prev":"b83416e7e2f9df6f9dd2d888a91b2df4982cb68216851eaa4be01fd0cc9787e8","hash":"ed0fcbc7110d980f65a884e8e57afc8f2bb22e0fc66eeb230cb37e3f5b279832"},{"id":"s29","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1e4ai7g/tesamorelin_no_recomp_occurring/","title":"Tesamorelin - no recomp occurring","quote":"I had to go back up a lot on a medication for nerve pain called Lyrica","summary":"User mention of nerve pain medication alongside tesamorelin use.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:24:03.648Z","link_status":"ok","quote_status":"unverified","prev":"ed0fcbc7110d980f65a884e8e57afc8f2bb22e0fc66eeb230cb37e3f5b279832","hash":"61139c36383c74cf77b3786512b24ea446e6018a64c0d0613657a533819f3b6b"},{"id":"s35","type":"reddit","url":"https://www.reddit.com/r/Peptidesource/comments/1o3ffie/tesamorelinipamorelin_side_effects/","title":"Tesamorelin/ipamorelin side effects","quote":"Has anyone had terrible numbness n hands using tesa??","summary":"Anecdotal reports of numbness with tesamorelin.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:24:03.648Z","link_status":"ok","quote_status":"unverified","prev":"61139c36383c74cf77b3786512b24ea446e6018a64c0d0613657a533819f3b6b","hash":"9a9a58100494144d7b90983b46cde52f18df4fbf820b18283c3f1de948a38e30"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:24:04.217Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for Diabetic Neuropathy: Evidence Review","register":"source_ledger","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy involves progressive nerve damage tied to long-term high blood sugar. Layers include axonal degeneration, myelin sheath breakdown, reduced blood flow to nerves, and impaired nerve repair signals. If your condition includes these, degeneration outpaces the body's natural repair processes. The focus here stays on pathways that might support repair rather than suppress symptoms like pain.\n\n## Why Tesamorelin might help you\n\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\n2. **Therefore for you:** If the GH axis or visceral fat layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nTesamorelin acts as a growth hormone-releasing hormone analog. It prompts the pituitary to release more growth hormone, which in turn raises IGF-1 levels. Growth hormone and IGF-1 have been linked in animal models to supporting axonal regeneration after nerve injury. If your neuropathy involves slowed nerve regrowth, this pathway could relate to repair mechanisms rather than symptom control.\n\nIn a human study of type 2 diabetes patients, 12 weeks of tesamorelin did not worsen insulin response, fasting glucose, or HbA1c compared to placebo (human data). This matters if metabolic stability is a concern alongside neuropathy. No direct link to nerve repair in diabetic neuropathy appears in available records.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Tesamorelin** → GH axis / visceral fat\n\nThe discussion centers on one layer only: potential support for GH-mediated tissue repair signals. No stacking details apply here.\n\n## What the evidence actually shows\n\nNo completed human trials test tesamorelin specifically for diabetic neuropathy (human tier: absence of data). A planned clinical trial (NCT03150511) examines tesamorelin for recovery after traumatic peripheral nerve injury, not diabetic cases; results are not yet available (human tier: planned study).\n\nOne 12-week human trial in type 2 diabetic patients found tesamorelin did not change glycemic control or insulin sensitivity versus placebo (human data, source s5). Animal studies show growth hormone can speed peripheral nerve regeneration and reduce muscle atrophy after injury (preclinical tier).\n\nFDA labels and trials report paresthesia, hypoesthesia, and peripheral neuropathy as adverse events in some patients (human tier). FAERS data links tesamorelin to higher reporting of carpal tunnel syndrome (human tier, source s18).\n\n## What scientists say\n\nResearchers note growth hormone's role in nerve regeneration from animal work. The Johns Hopkins trial aims to test whether tesamorelin improves functional outcomes after nerve repair by boosting this pathway. Scientists highlight the need for human data specific to diabetic neuropathy, which remains absent. Metabolic studies in diabetics provide reassurance on short-term glucose stability but do not address neuropathy progression.\n\n## What people say on Reddit\n\nAnecdotal reports mention side effects such as hand numbness or carpal tunnel-like symptoms during tesamorelin use; some users link these to the compound and note resolution after stopping (anecdotal tier). Discussions reference the peripheral nerve injury trial with interest in regeneration potential, but no personal accounts describe benefits for diabetic neuropathy (anecdotal tier). Posts about nerve pain often appear in unrelated contexts.\n\n## What people say on X\n\nLimited public posts discuss tesamorelin in neuropathy contexts. Mentions focus on general GH benefits or trial awareness rather than personal diabetic neuropathy experiences (anecdotal tier, sparse).\n\n## What we do not know\n\nDirect evidence on tesamorelin altering diabetic neuropathy progression, nerve conduction, or symptoms in humans is missing. Long-term effects on nerve repair in diabetic populations remain untested. Interactions with existing diabetic neuropathy treatments lack study data. Whether GH elevation translates to meaningful repair in chronic metabolic nerve damage versus acute injury stays speculative.\n\n## Safety and limits\n\nTesamorelin carries warnings for potential glucose intolerance and diabetes risk; monitoring is advised in diabetic patients (human data). It is contraindicated in active cancer or certain pituitary issues. Injection site reactions and fluid retention appear in trials. All claims here derive from available studies and labels; no compound guarantees repair or safety for any individual condition. Evidence grading separates clear human trial results from animal work and user reports.","claims":[{"id":"c1","text":"No completed human trials test tesamorelin specifically for diabetic neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s0"],"source_status":"sourced","why_material":"Establishes absence of direct evidence for the condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A 12-week human trial in type 2 diabetic patients found tesamorelin did not alter insulin response or glycemic control versus placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Provides metabolic safety data relevant to diabetic readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Animal studies indicate growth hormone can accelerate peripheral nerve regeneration after injury.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Supports mechanistic rationale but does not prove human diabetic neuropathy benefit.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Tesamorelin is associated with reports of paresthesia, hypoesthesia, and peripheral neuropathy in clinical data.","section":"What the evidence actually shows","tier":"human","source_ids":["s7"],"source_status":"sourced","why_material":"Highlights potential adverse nerve-related effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users report numbness or carpal tunnel-like symptoms during tesamorelin use, sometimes resolving after discontinuation.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s29","s35"],"source_status":"sourced","why_material":"Captures user experiences separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries.","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"pubmed","url":"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179538","title":"Safety and metabolic effects of tesamorelin in type 2 diabetic patients","quote":"Treatment of type 2 diabetic patients with tesamorelin for 12 weeks did not alter insulin response or glycemic control.","link_status":"ok","quote_status":"verified"},{"id":"s1","type":"other","url":"https://www.foundationforpn.org/wp-content/uploads/2025/01/Tesamorelin-Therapy-to-Enhance-Axonal-Regeneration-Minimize-Muscle-Atrophy-and-Improve-Functional-Outcomes-Following-Peripheral-Nerve-Injury-and-Repair.pdf","title":"Tesamorelin Therapy for Peripheral Nerve Injury Proposal","quote":"Many animal studies have shown that growth hormone, via its downstream factors, can speed peripheral nerve regeneration following injury","link_status":"ok","quote_status":"unverified"},{"id":"s7","type":"other","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf","title":"EGRIFTA (tesamorelin) FDA Label","quote":"Hypoesthesia 4.2% vs 1.5% placebo; Neuropathy peripheral listed in adverse reactions.","link_status":"ok","quote_status":"unverified"},{"id":"s29","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1e4ai7g/tesamorelin_no_recomp_occurring/","title":"Tesamorelin - no recomp occurring","quote":"I had to go back up a lot on a medication for nerve pain called Lyrica","link_status":"ok","quote_status":"unverified"},{"id":"s35","type":"reddit","url":"https://www.reddit.com/r/Peptidesource/comments/1o3ffie/tesamorelinipamorelin_side_effects/","title":"Tesamorelin/ipamorelin side effects","quote":"Has anyone had terrible numbness n hands using tesa??","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":24041,"tokens_out":3340,"cost":0.03840125,"prev_hash":"genesis","hash":"8abae562b5def2794af9700ab9fc21eace64049c9e6135a24068dfd6745d0bc5"}],"provenance":[{"ts":"2026-06-29T23:24:04.217Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Diabetic Neuropathy\nSlug: tesamorelin-diabetic-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"Diabetic neuropathy\",\"condition_key\":\"diabetic-neuropathy\",\"primary_peptide\":\"tesamorelin\",\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Diabetic neuropathy\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down if you","response":"{\n  \"slug\": \"tesamorelin-diabetic-neuropathy\",\n  \"title\": \"Tesamorelin for Diabetic Neuropathy: Evidence Review\",\n  \"body\": \"## What's breaking down if you have Diabetic neuropathy\\n\\nDiabetic neuropathy involves progressive nerve damage tied to long-term high blood sugar. Layers include axonal degeneration, myelin sheath breakdown, reduced blood flow to nerves, and impaired nerve repair signals. If your condition includes these, degeneration outpaces the body's natural repair processes. The focus here stays on pathways that might support repair rather than suppress symptoms like pain.\\n\\n## Why Tesamorelin might help you\\n\\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If the GH axis or visceral fat layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nTesamorelin acts as a growth hormone-releasing hormone analog. It prompts the pituitary to release more growth hormone, which in turn raises IGF-1 levels. Growth hormone and IGF-1 have been linked in animal models to supporting axonal regeneration after nerve injury. If your neuropathy involves slowed nerve regrowth, this pathway could relate to repair mechanisms rather than symptom control.\\n\\nIn a human study of type 2 diabetes patients, 12 weeks of tesamorelin did not worsen insulin response, fasting glucose, or HbA1c compared to placebo (human data). This matters if metabolic stability is a concern alongside neuropathy. No direct link to nerve repair in diabetic neuropathy appears in available records.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\\n\\nThe discussion centers on one layer only: potential support for GH-mediated tissue repair signals. No stacking details apply here.\\n\\n## What the","tokens_in":24041,"tokens_out":3340,"cost":0,"prev":"genesis","hash":"646f29e4ab0e39739507733de9ba0310116a780866493d03a638fb2d2c33b0d1"},{"ts":"2026-07-17T02:42:21.877Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-diabetic-neuropathy","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"646f29e4ab0e39739507733de9ba0310116a780866493d03a638fb2d2c33b0d1","hash":"617f427a9e57fb5176705311c419b78b3143406294e99f5870d57e06841046d7"}],"energy":{"passes":2,"tokens_in":24041,"tokens_out":3340,"tokens_total":27381,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"617f427a9e57fb5176705311c419b78b3143406294e99f5870d57e06841046d7"},"posted_at":"2026-06-29T21:33:32.050Z","created_at":"2026-06-29T21:33:32.050Z","updated_at":"2026-07-17T02:42:21.877Z","machine":{"shape":"article.machine/v1","slug":"tesamorelin-diabetic-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/tesamorelin-diabetic-neuropathy","json":"https://miscsubjects.com/api/articles/tesamorelin-diabetic-neuropathy","bundle":"https://miscsubjects.com/api/articles/tesamorelin-diabetic-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":6,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tesamorelin-diabetic-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tesamorelin-diabetic-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-diabetic-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-diabetic-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tesamorelin-diabetic-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tesamorelin-diabetic-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tesamorelin-diabetic-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tesamorelin-diabetic-neuropathy","json":"/api/articles/tesamorelin-diabetic-neuropathy","markdown":"/api/articles/tesamorelin-diabetic-neuropathy/bundle?format=markdown","skill":"/api/articles/tesamorelin-diabetic-neuropathy/skill","topology":"/api/articles/tesamorelin-diabetic-neuropathy/topology","versions":"/api/articles/tesamorelin-diabetic-neuropathy/revisions","invocations":"/api/articles/tesamorelin-diabetic-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tesamorelin-diabetic-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"4eff26e8382247a1706dc01c30aad4640d7f886ae35d5d12affa4db53656d0fd","object":{"object_type":"article-object","identity":{"id":"article:tesamorelin-diabetic-neuropathy","slug":"tesamorelin-diabetic-neuropathy","title":"Tesamorelin for Diabetic Neuropathy: Evidence Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/tesamorelin-diabetic-neuropathy","role":"explain","audience":"human"},"skill":{"route":"/api/articles/tesamorelin-diabetic-neuropathy/skill","role":"direct behavior","audience":"model","content":"---\nname: tesamorelin-diabetic-neuropathy\ndescription: Apply the Tesamorelin for Diabetic Neuropathy: Evidence Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Tesamorelin for Diabetic Neuropathy: Evidence Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/tesamorelin-diabetic-neuropathy). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/tesamorelin-diabetic-neuropathy.\n- Read claims and relationships at /api/articles/tesamorelin-diabetic-neuropathy/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down if you have Diabetic neuropathy Diabetic neuropathy involves progressive nerve damage tied to long-term high blood sugar. Layers include axonal degeneration, myelin sheath breakdown, reduced blood flow to nerves, and im\n\n## Representations\n\n- Human: /a/tesamorelin-diabetic-neuropathy\n- JSON: /api/articles/tesamorelin-diabetic-neuropathy\n- Relationships: /api/articles/tesamorelin-diabetic-neuropathy/topology\n- History: /api/articles/tesamorelin-diabetic-neuropathy/revisions\n"},"json":{"route":"/api/articles/tesamorelin-diabetic-neuropathy","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/tesamorelin-diabetic-neuropathy/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","tesamorelin","diabetic","neuropathy"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/tesamorelin-diabetic-neuropathy/invocations?status=success","failure_events":"/api/articles/tesamorelin-diabetic-neuropathy/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"tesamorelin-diabetic-neuropathy","title":"Tesamorelin for Diabetic Neuropathy: Evidence Review","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy involves progressive nerve damage tied to long-term high blood sugar. Layers include axonal degeneration, myelin sheath breakdown, reduced blood flow to nerves, and impaired nerve repair signals. If your condition includes these, degeneration outpaces the body's natural repair processes. The focus here stays on pathways that might support repair rather than suppress symptoms like pain.\n\n## Why Tesamorelin might help you\n\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\n2. **Therefore for you:** If the GH axis or visceral fat layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nTesamorelin acts as a growth hormone-releasing hormone analog. It prompts the pituitary to release more growth hormone, which in turn raises IGF-1 levels. Growth hormone and IGF-1 have been linked in animal models to supporting axonal regeneration after nerve injury. If your neuropathy involves slowed nerve regrowth, this pathway could relate to repair mechanisms rather than symptom control.\n\nIn a human study of type 2 diabetes patients, 12 weeks of tesamorelin did not worsen insulin response, fasting glucose, or HbA1c compared to placebo (human data). This matters if metabolic stability is a concern alongside neuropathy. No direct link to nerve repair in diabetic neuropathy appears in available records.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Tesamorelin** → GH axis / visceral fat\n\nThe discussion centers on one layer only: potential support for GH-mediated tissue repair signals. No stacking details apply here.\n\n## What the evidence actually shows\n\nNo completed human trials test tesamorelin specifically for diabetic neuropathy (human tier: absence of data). A planned clinical trial (NCT03150511) examines tesamorelin for recovery after traumatic peripheral nerve injury, not diabetic cases; results are not yet available (human tier: planned study).\n\nOne 12-week human trial in type 2 diabetic patients found tesamorelin did not change glycemic control or insulin sensitivity versus placebo (human data, source s5). Animal studies show growth hormone can speed peripheral nerve regeneration and reduce muscle atrophy after injury (preclinical tier).\n\nFDA labels and trials report paresthesia, hypoesthesia, and peripheral neuropathy as adverse events in some patients (human tier). FAERS data links tesamorelin to higher reporting of carpal tunnel syndrome (human tier, source s18).\n\n## What scientists say\n\nResearchers note growth hormone's role in nerve regeneration from animal work. The Johns Hopkins trial aims to test whether tesamorelin improves functional outcomes after nerve repair by boosting this pathway. Scientists highlight the need for human data specific to diabetic neuropathy, which remains absent. Metabolic studies in diabetics provide reassurance on short-term glucose stability but do not address neuropathy progression.\n\n## What people say on Reddit\n\nAnecdotal reports mention side effects such as hand numbness or carpal tunnel-like symptoms during tesamorelin use; some users link these to the compound and note resolution after stopping (anecdotal tier). Discussions reference the peripheral nerve injury trial with interest in regeneration potential, but no personal accounts describe benefits for diabetic neuropathy (anecdotal tier). Posts about nerve pain often appear in unrelated contexts.\n\n## What people say on X\n\nLimited public posts discuss tesamorelin in neuropathy contexts. Mentions focus on general GH benefits or trial awareness rather than personal diabetic neuropathy experiences (anecdotal tier, sparse).\n\n## What we do not know\n\nDirect evidence on tesamorelin altering diabetic neuropathy progression, nerve conduction, or symptoms in humans is missing. Long-term effects on nerve repair in diabetic populations remain untested. Interactions with existing diabetic neuropathy treatments lack study data. Whether GH elevation translates to meaningful repair in chronic metabolic nerve damage versus acute injury stays speculative.\n\n## Safety and limits\n\nTesamorelin carries warnings for potential glucose intolerance and diabetes risk; monitoring is advised in diabetic patients (human data). It is contraindicated in active cancer or certain pituitary issues. Injection site reactions and fluid retention appear in trials. All claims here derive from available studies and labels; no compound guarantees repair or safety for any individual condition. Evidence grading separates clear human trial results from animal work and user reports.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tesamorelin-diabetic-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"No completed human trials test tesamorelin specifically for diabetic neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s0"],"source_status":"sourced","why_material":"Establishes absence of direct evidence for the condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A 12-week human trial in type 2 diabetic patients found tesamorelin did not alter insulin response or glycemic control versus placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Provides metabolic safety data relevant to diabetic readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Animal studies indicate growth hormone can accelerate peripheral nerve regeneration after injury.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Supports mechanistic rationale but does not prove human diabetic neuropathy benefit.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Tesamorelin is associated with reports of paresthesia, hypoesthesia, and peripheral neuropathy in clinical data.","section":"What the evidence actually shows","tier":"human","source_ids":["s7"],"source_status":"sourced","why_material":"Highlights potential adverse nerve-related effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users report numbness or carpal tunnel-like symptoms during tesamorelin use, sometimes resolving after discontinuation.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s29","s35"],"source_status":"sourced","why_material":"Captures user experiences separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries.","summary":"Ongoing/planned trial for traumatic nerve injury, not diabetic neuropathy.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:24:03.648Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"8e0e6de4e112963b3a44c240e786ceec91170d3473d3893393a9a91b47157c0f"},{"id":"s5","type":"pubmed","url":"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179538","title":"Safety and metabolic effects of tesamorelin in type 2 diabetic patients","quote":"Treatment of type 2 diabetic patients with tesamorelin for 12 weeks did not alter insulin response or glycemic control.","summary":"Human metabolic study in diabetics showing neutral effect on glucose control.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:24:03.648Z","link_status":"ok","quote_status":"verified","prev":"8e0e6de4e112963b3a44c240e786ceec91170d3473d3893393a9a91b47157c0f","hash":"302b8b27b3f37df95eedd0a8a447999ec830d58bfc69cf06868f9f42ec01eb8a"},{"id":"s1","type":"other","url":"https://www.foundationforpn.org/wp-content/uploads/2025/01/Tesamorelin-Therapy-to-Enhance-Axonal-Regeneration-Minimize-Muscle-Atrophy-and-Improve-Functional-Outcomes-Following-Peripheral-Nerve-Injury-and-Repair.pdf","title":"Tesamorelin Therapy for Peripheral Nerve Injury Proposal","quote":"Many animal studies have shown that growth hormone, via its downstream factors, can speed peripheral nerve regeneration following injury","summary":"Background on preclinical GH nerve regeneration data.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:24:03.648Z","link_status":"ok","quote_status":"unverified","prev":"302b8b27b3f37df95eedd0a8a447999ec830d58bfc69cf06868f9f42ec01eb8a","hash":"b83416e7e2f9df6f9dd2d888a91b2df4982cb68216851eaa4be01fd0cc9787e8"},{"id":"s7","type":"other","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf","title":"EGRIFTA (tesamorelin) FDA Label","quote":"Hypoesthesia 4.2% vs 1.5% placebo; Neuropathy peripheral listed in adverse reactions.","summary":"Adverse event data including nerve symptoms.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:24:03.648Z","link_status":"ok","quote_status":"unverified","prev":"b83416e7e2f9df6f9dd2d888a91b2df4982cb68216851eaa4be01fd0cc9787e8","hash":"ed0fcbc7110d980f65a884e8e57afc8f2bb22e0fc66eeb230cb37e3f5b279832"},{"id":"s29","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1e4ai7g/tesamorelin_no_recomp_occurring/","title":"Tesamorelin - no recomp occurring","quote":"I had to go back up a lot on a medication for nerve pain called Lyrica","summary":"User mention of nerve pain medication alongside tesamorelin use.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:24:03.648Z","link_status":"ok","quote_status":"unverified","prev":"ed0fcbc7110d980f65a884e8e57afc8f2bb22e0fc66eeb230cb37e3f5b279832","hash":"61139c36383c74cf77b3786512b24ea446e6018a64c0d0613657a533819f3b6b"},{"id":"s35","type":"reddit","url":"https://www.reddit.com/r/Peptidesource/comments/1o3ffie/tesamorelinipamorelin_side_effects/","title":"Tesamorelin/ipamorelin side effects","quote":"Has anyone had terrible numbness n hands using tesa??","summary":"Anecdotal reports of numbness with tesamorelin.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:24:03.648Z","link_status":"ok","quote_status":"unverified","prev":"61139c36383c74cf77b3786512b24ea446e6018a64c0d0613657a533819f3b6b","hash":"9a9a58100494144d7b90983b46cde52f18df4fbf820b18283c3f1de948a38e30"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:24:04.217Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for Diabetic Neuropathy: Evidence Review","register":"source_ledger","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy involves progressive nerve damage tied to long-term high blood sugar. Layers include axonal degeneration, myelin sheath breakdown, reduced blood flow to nerves, and impaired nerve repair signals. If your condition includes these, degeneration outpaces the body's natural repair processes. The focus here stays on pathways that might support repair rather than suppress symptoms like pain.\n\n## Why Tesamorelin might help you\n\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\n2. **Therefore for you:** If the GH axis or visceral fat layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nTesamorelin acts as a growth hormone-releasing hormone analog. It prompts the pituitary to release more growth hormone, which in turn raises IGF-1 levels. Growth hormone and IGF-1 have been linked in animal models to supporting axonal regeneration after nerve injury. If your neuropathy involves slowed nerve regrowth, this pathway could relate to repair mechanisms rather than symptom control.\n\nIn a human study of type 2 diabetes patients, 12 weeks of tesamorelin did not worsen insulin response, fasting glucose, or HbA1c compared to placebo (human data). This matters if metabolic stability is a concern alongside neuropathy. No direct link to nerve repair in diabetic neuropathy appears in available records.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Tesamorelin** → GH axis / visceral fat\n\nThe discussion centers on one layer only: potential support for GH-mediated tissue repair signals. No stacking details apply here.\n\n## What the evidence actually shows\n\nNo completed human trials test tesamorelin specifically for diabetic neuropathy (human tier: absence of data). A planned clinical trial (NCT03150511) examines tesamorelin for recovery after traumatic peripheral nerve injury, not diabetic cases; results are not yet available (human tier: planned study).\n\nOne 12-week human trial in type 2 diabetic patients found tesamorelin did not change glycemic control or insulin sensitivity versus placebo (human data, source s5). Animal studies show growth hormone can speed peripheral nerve regeneration and reduce muscle atrophy after injury (preclinical tier).\n\nFDA labels and trials report paresthesia, hypoesthesia, and peripheral neuropathy as adverse events in some patients (human tier). FAERS data links tesamorelin to higher reporting of carpal tunnel syndrome (human tier, source s18).\n\n## What scientists say\n\nResearchers note growth hormone's role in nerve regeneration from animal work. The Johns Hopkins trial aims to test whether tesamorelin improves functional outcomes after nerve repair by boosting this pathway. Scientists highlight the need for human data specific to diabetic neuropathy, which remains absent. Metabolic studies in diabetics provide reassurance on short-term glucose stability but do not address neuropathy progression.\n\n## What people say on Reddit\n\nAnecdotal reports mention side effects such as hand numbness or carpal tunnel-like symptoms during tesamorelin use; some users link these to the compound and note resolution after stopping (anecdotal tier). Discussions reference the peripheral nerve injury trial with interest in regeneration potential, but no personal accounts describe benefits for diabetic neuropathy (anecdotal tier). Posts about nerve pain often appear in unrelated contexts.\n\n## What people say on X\n\nLimited public posts discuss tesamorelin in neuropathy contexts. Mentions focus on general GH benefits or trial awareness rather than personal diabetic neuropathy experiences (anecdotal tier, sparse).\n\n## What we do not know\n\nDirect evidence on tesamorelin altering diabetic neuropathy progression, nerve conduction, or symptoms in humans is missing. Long-term effects on nerve repair in diabetic populations remain untested. Interactions with existing diabetic neuropathy treatments lack study data. Whether GH elevation translates to meaningful repair in chronic metabolic nerve damage versus acute injury stays speculative.\n\n## Safety and limits\n\nTesamorelin carries warnings for potential glucose intolerance and diabetes risk; monitoring is advised in diabetic patients (human data). It is contraindicated in active cancer or certain pituitary issues. Injection site reactions and fluid retention appear in trials. All claims here derive from available studies and labels; no compound guarantees repair or safety for any individual condition. Evidence grading separates clear human trial results from animal work and user reports.","claims":[{"id":"c1","text":"No completed human trials test tesamorelin specifically for diabetic neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s0"],"source_status":"sourced","why_material":"Establishes absence of direct evidence for the condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A 12-week human trial in type 2 diabetic patients found tesamorelin did not alter insulin response or glycemic control versus placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Provides metabolic safety data relevant to diabetic readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Animal studies indicate growth hormone can accelerate peripheral nerve regeneration after injury.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Supports mechanistic rationale but does not prove human diabetic neuropathy benefit.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Tesamorelin is associated with reports of paresthesia, hypoesthesia, and peripheral neuropathy in clinical data.","section":"What the evidence actually shows","tier":"human","source_ids":["s7"],"source_status":"sourced","why_material":"Highlights potential adverse nerve-related effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users report numbness or carpal tunnel-like symptoms during tesamorelin use, sometimes resolving after discontinuation.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s29","s35"],"source_status":"sourced","why_material":"Captures user experiences separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:24:03.824Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries.","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"pubmed","url":"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179538","title":"Safety and metabolic effects of tesamorelin in type 2 diabetic patients","quote":"Treatment of type 2 diabetic patients with tesamorelin for 12 weeks did not alter insulin response or glycemic control.","link_status":"ok","quote_status":"verified"},{"id":"s1","type":"other","url":"https://www.foundationforpn.org/wp-content/uploads/2025/01/Tesamorelin-Therapy-to-Enhance-Axonal-Regeneration-Minimize-Muscle-Atrophy-and-Improve-Functional-Outcomes-Following-Peripheral-Nerve-Injury-and-Repair.pdf","title":"Tesamorelin Therapy for Peripheral Nerve Injury Proposal","quote":"Many animal studies have shown that growth hormone, via its downstream factors, can speed peripheral nerve regeneration following injury","link_status":"ok","quote_status":"unverified"},{"id":"s7","type":"other","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf","title":"EGRIFTA (tesamorelin) FDA Label","quote":"Hypoesthesia 4.2% vs 1.5% placebo; Neuropathy peripheral listed in adverse reactions.","link_status":"ok","quote_status":"unverified"},{"id":"s29","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1e4ai7g/tesamorelin_no_recomp_occurring/","title":"Tesamorelin - no recomp occurring","quote":"I had to go back up a lot on a medication for nerve pain called Lyrica","link_status":"ok","quote_status":"unverified"},{"id":"s35","type":"reddit","url":"https://www.reddit.com/r/Peptidesource/comments/1o3ffie/tesamorelinipamorelin_side_effects/","title":"Tesamorelin/ipamorelin side effects","quote":"Has anyone had terrible numbness n hands using tesa??","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":24041,"tokens_out":3340,"cost":0.03840125,"prev_hash":"genesis","hash":"8abae562b5def2794af9700ab9fc21eace64049c9e6135a24068dfd6745d0bc5"}],"provenance":[{"ts":"2026-06-29T23:24:04.217Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Diabetic Neuropathy\nSlug: tesamorelin-diabetic-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"Diabetic neuropathy\",\"condition_key\":\"diabetic-neuropathy\",\"primary_peptide\":\"tesamorelin\",\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Diabetic neuropathy\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down if you","response":"{\n  \"slug\": \"tesamorelin-diabetic-neuropathy\",\n  \"title\": \"Tesamorelin for Diabetic Neuropathy: Evidence Review\",\n  \"body\": \"## What's breaking down if you have Diabetic neuropathy\\n\\nDiabetic neuropathy involves progressive nerve damage tied to long-term high blood sugar. Layers include axonal degeneration, myelin sheath breakdown, reduced blood flow to nerves, and impaired nerve repair signals. If your condition includes these, degeneration outpaces the body's natural repair processes. The focus here stays on pathways that might support repair rather than suppress symptoms like pain.\\n\\n## Why Tesamorelin might help you\\n\\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If the GH axis or visceral fat layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nTesamorelin acts as a growth hormone-releasing hormone analog. It prompts the pituitary to release more growth hormone, which in turn raises IGF-1 levels. Growth hormone and IGF-1 have been linked in animal models to supporting axonal regeneration after nerve injury. If your neuropathy involves slowed nerve regrowth, this pathway could relate to repair mechanisms rather than symptom control.\\n\\nIn a human study of type 2 diabetes patients, 12 weeks of tesamorelin did not worsen insulin response, fasting glucose, or HbA1c compared to placebo (human data). This matters if metabolic stability is a concern alongside neuropathy. No direct link to nerve repair in diabetic neuropathy appears in available records.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\\n\\nThe discussion centers on one layer only: potential support for GH-mediated tissue repair signals. No stacking details apply here.\\n\\n## What the","tokens_in":24041,"tokens_out":3340,"cost":0,"prev":"genesis","hash":"646f29e4ab0e39739507733de9ba0310116a780866493d03a638fb2d2c33b0d1"},{"ts":"2026-07-17T02:42:21.877Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-diabetic-neuropathy","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"646f29e4ab0e39739507733de9ba0310116a780866493d03a638fb2d2c33b0d1","hash":"617f427a9e57fb5176705311c419b78b3143406294e99f5870d57e06841046d7"}],"energy":{"passes":2,"tokens_in":24041,"tokens_out":3340,"tokens_total":27381,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"617f427a9e57fb5176705311c419b78b3143406294e99f5870d57e06841046d7"},"posted_at":"2026-06-29T21:33:32.050Z","created_at":"2026-06-29T21:33:32.050Z","updated_at":"2026-07-17T02:42:21.877Z","machine":{"shape":"article.machine/v1","slug":"tesamorelin-diabetic-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/tesamorelin-diabetic-neuropathy","json":"https://miscsubjects.com/api/articles/tesamorelin-diabetic-neuropathy","bundle":"https://miscsubjects.com/api/articles/tesamorelin-diabetic-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":6,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tesamorelin-diabetic-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tesamorelin-diabetic-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-diabetic-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-diabetic-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tesamorelin-diabetic-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tesamorelin-diabetic-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tesamorelin-diabetic-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tesamorelin-diabetic-neuropathy","json":"/api/articles/tesamorelin-diabetic-neuropathy","markdown":"/api/articles/tesamorelin-diabetic-neuropathy/bundle?format=markdown","skill":"/api/articles/tesamorelin-diabetic-neuropathy/skill","topology":"/api/articles/tesamorelin-diabetic-neuropathy/topology","versions":"/api/articles/tesamorelin-diabetic-neuropathy/revisions","invocations":"/api/articles/tesamorelin-diabetic-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tesamorelin-diabetic-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"4eff26e8382247a1706dc01c30aad4640d7f886ae35d5d12affa4db53656d0fd"}}}